Jul 18, 2010 - 11:17 pm
By AP Jul 16th 2010 11:42AM
The Food and Drug Administration approved Roche's blockbuster Avastin in 2008 based on early-stage trials showing it shrank tumors caused by breast cancer. The approval was controversial because such drugs are usually required to show increased survival time for patients.
The FDA says follow-up studies recently submitted by Roche failed to show that Avastin extended lives compared to chemotherapy alone.
On Tuesday the FDA will ask a panel of outside cancer experts to review the evidence on Avastin.
The FDA has the option to remove drug from the market.
Copyright 2010 The Associated Press. The information contained in the AP news report may not be published, broadcast, rewritten or otherwise distributed without the prior written authority of The Associated Press. All active hyperlinks have been inserted by AOL.
More on Breast Cancer: